Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.
2.

Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.

Lilleri D, Baldanti F, Gatti M, Rovida F, Dossena L, De Grazia S, Torsellini M, Gerna G.

J Med Virol. 2004 Jul;73(3):412-8.

PMID:
15170637
3.

Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients.

Gerna G, Lilleri D, Furione M, Castiglioni B, Meloni F, Rampino T, Agozzino M, Arbustini E.

New Microbiol. 2012 Jul;35(3):279-87. Epub 2012 Jun 30.

4.

Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation.

Gerna G, Lilleri D, Chiesa A, Zelini P, Furione M, Comolli G, Pellegrini C, Sarchi E, Migotto C, Bonora MR, Meloni F, Arbustini E.

Am J Transplant. 2011 Nov;11(11):2463-71. doi: 10.1111/j.1600-6143.2011.03636.x. Epub 2011 Aug 9.

5.

Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients.

Gabanti E, Bruno F, Lilleri D, Fornara C, Zelini P, Cane I, Migotto C, Sarchi E, Furione M, Gerna G.

PLoS One. 2014 Aug 28;9(8):e106044. doi: 10.1371/journal.pone.0106044. eCollection 2014.

6.

Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients.

Gerna G, Lilleri D, Rognoni V, Agozzino M, Meloni F, Oggionni T, Pellegrini C, Arbustini E, D'Armini AM.

Am J Transplant. 2009 May;9(5):1142-50. doi: 10.1111/j.1600-6143.2009.02616.x.

7.
8.

Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host.

Lilleri D, Zelini P, Fornara C, Comolli G, Revello MG, Gerna G.

Clin Immunol. 2009 Jun;131(3):395-403. doi: 10.1016/j.clim.2009.02.002. Epub 2009 Mar 5.

PMID:
19268633
9.

Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation.

Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C, Pellegrini C, Meloni F, Rampino T.

Am J Transplant. 2006 Oct;6(10):2356-64. Epub 2006 Aug 1.

10.

Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.

Lilleri D, Gerna G, Zelini P, Chiesa A, Rognoni V, Mastronuzzi A, Giorgiani G, Zecca M, Locatelli F.

PLoS One. 2012;7(7):e41648. doi: 10.1371/journal.pone.0041648. Epub 2012 Jul 25.

11.

Monitoring transplant patients for human cytomegalovirus: Diagnostic update.

Gerna G, Lilleri D.

Herpes. 2006 May;13(1):4-11. Review.

PMID:
16732996
12.

Monitoring human cytomegalovirus infection in transplant recipients.

Baldanti F, Lilleri D, Gerna G.

J Clin Virol. 2008 Mar;41(3):237-41. doi: 10.1016/j.jcv.2007.12.001. Epub 2008 Jan 18. Review.

PMID:
18203657
13.

Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.

Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G.

Haematologica. 2008 Feb;93(2):248-56. doi: 10.3324/haematol.11912.

14.

Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.

Hebart H, Rudolph T, Loeffler J, Middeldorp J, Ljubicic T, Jahn G, Einsele H.

Bone Marrow Transplant. 2002 Aug;30(3):181-7.

15.

Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation.

Baldanti F, Lilleri D, Gerna G.

Hematol Oncol. 2008 Sep;26(3):123-30. doi: 10.1002/hon.856. Review.

PMID:
18386849
17.

Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.

Gerna G, Baldanti F, Torsellini M, Minoli L, ViganĂ² M, Oggionnis T, Rampino T, Castiglioni B, Goglio A, Colledan M, Mammana C, Nozza F, Daniele L; Bergamo Transplant Group.

Antivir Ther. 2007;12(1):63-72.

PMID:
17503749
18.

Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.

Gabanti E, Lilleri D, Ripamonti F, Bruno F, Zelini P, Furione M, Colombo AA, Alessandrino EP, Gerna G.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2192-2202. doi: 10.1016/j.bbmt.2015.08.002. Epub 2015 Aug 8.

19.

Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy.

Brestrich G, Zwinger S, Roemhild A, Noutsias M, Rohde M, Keeren K, Sawitzki B, Volk HD, Reinke P, Hammer MH.

J Immunother. 2009 Nov-Dec;32(9):932-40. doi: 10.1097/CJI.0b013e3181b88fda.

PMID:
19816188
20.

Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation.

Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M, Rauser G, Sinzger C, Jahn G, Loeffler J, Kanz L, Rammensee HG, Einsele H.

Blood. 2002 May 15;99(10):3830-7.

Supplemental Content

Support Center